3.71
-0.32 (-7.94%)
| Previous Close | 4.03 |
| Volume | 161,315 |
| Price / Sales | 90.99 |
| Price / Book | 0.530 |
| 52 Weeks Range | |
| TTM Dividend Yield | 6.74% |
| Operating Margin (TTM) | -225.00% |
| Diluted EPS (TTM) | -0.710 |
| Total Debt/Equity (MRQ) | 0.22% |
| Current Ratio (MRQ) | 23.94 |
| Operating Cash Flow (TTM) | -10.46 M |
| Levered Free Cash Flow (TTM) | -1.51 M |
| Return on Assets (TTM) | -5.10% |
| Return on Equity (TTM) | -18.51% |
AIStockmoo Score
| Value 30% | 0.0 |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info | |
| Return on Capital info | NA |
| Timing 30% | -0.5 |
| From our AI technical analysis of the chart. info | NA |
| Uptrend over the past year. Far below its 52-week high. info | |
| Candle Patterns info | NA |
| Trend for Your Holding Period info | NA |
| Sentiment 20% | 0.0 |
| No recent price targets, so based on how targets have been revised. info | |
| News Mood info | NA |
| Smart Money 20% | 3.2 |
| Insider Activity info | NA |
| Institutions net +18.26% of shares in their latest 13F filings: 56 holders increased, 23 decreased (quarter to 30 Sep 2026). info | |
| Short interest +16.4% from 31 Aug to 30 Oct 2026, 11.3 days to cover (FINRA). info | |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Price is near its 52-week average. Down over 5 years. info | |
| Short-term momentum falling. info | |
| Price is between support and resistance. Levels trending down. info | |
| Final Score | 0.46 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Oramed Pharmaceuticals Inc. | Mixed | Mixed |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| ORMP | - | 6.74% | - | 0.530 |
| OPT | 583 M | - | - | 4.31 |
| OCUP | 51 M | - | - | 0.870 |
| CTMX | - | - | - | 1.55 |
| ZYME | - | - | - | 7.29 |
| PBYI | - | - | - | 2.73 |
Select this tab to load the latest available analysis.
|
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 13.21% |
| % Held by Institutions | 19.12% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sb Capital Management Inc | 31 Dec 2025 | 1,900,000 |
No data within this time range.
No data within this time range.
Institutions
Institutional ownership: 46.16%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 56 | 6,335,923 |
| Decreased | 23 | 704,680 |
| New | 23 | 2,573,118 |
| Sold out | 8 | 350,717 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 1,343,457 | 11.3 |
| 15 Oct 2026 | 1,451,095 | 10.4 |
| 30 Sep 2026 | 1,433,436 | 7.3 |
| 15 Sep 2026 | 1,307,745 | 7.4 |
| 31 Aug 2026 | 1,154,241 | 4.3 |
| 14 Aug 2026 | 1,025,767 | 5.9 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 12 Nov 2026 | Yahoo Finance |
Oramed: Q3 Earnings Snapshot
NEW YORK (AP) — NEW YORK (AP) — Oramed Pharmaceuticals Inc. (ORMP) on Thursday reported profit of $134… |
| 08 Sep 2026 | Yahoo Finance |
Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy
HUDSON, Mass. and YOKNEAM ILLIT, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced that an… |
| 28 Aug 2026 | Yahoo Finance |
ORMP: Investment Gains Contributed to Strong 2Q26 EPS, While Inclusion in Russell Indexes Arguably Boosts Awareness
By M. Marin NASDAQ: ORMP READ THE FULL ORMP RESEARCH REPORT Gains on investment portfolio + service agreement income contributed to 2Q26 EPS of $2.76 Oramed Pharmaceuticals (NASDAQ: ORMP) leverages its strong balance sheet, with $15.2 million of cash and equivalents and $50.6 million of cash and… |
| 17 Aug 2026 | Yahoo Finance |
Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee
WALTHAM, Mass., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension,” “Nano,” or the “Company”) today announced the appointment of Nadav Kidron to its Board of Directors (the “Board”). As part of the Board’s ongoing strategic review, led by Chairman Phillip… |
| TTM Dividend Yield | 6.74% |
| Expected Next Dividend Payment | Jan 2027 |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 16 Jan 2026 | - | 26 Jan 2026 | 0.25 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2026 | 0.250 | 1 | 6.74 |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |